The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Andrew F. Shorr

Department of Medicine

Pulmonary and Critical Care Medicine Division

Washington Hospital Center

Washington

USA

[email]@dnamail.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medicine, Pulmonary and Critical Care Medicine Division, Washington Hospital Center, Washington, USA. 2000 - 2012
  • Washington Hospital Center, Medstar, Potomac, USA. 2005 - 2009

References

  1. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Shorr, A.F., Zilberberg, M.D., Reichley, R., Kan, J., Hoban, A., Hoffman, J., Micek, S.T., Kollef, M.H. Clin. Infect. Dis. (2012) [Pubmed]
  2. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. Shorr, A.F., Wu, C., Kothari, S. J. Antimicrob. Chemother. (2011) [Pubmed]
  3. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). Shorr, A.F., Janes, J.M., Artigas, A., Tenhunen, J., Wyncoll, D.L., Mercier, E., Francois, B., Vincent, J.L., Vangerow, B., Heiselman, D., Leishman, A.G., Zhu, Y.E., Reinhart, K. Crit. Care (2010) [Pubmed]
  4. Candidemia on presentation to the hospital: development and validation of a risk score. Shorr, A.F., Tabak, Y.P., Johannes, R.S., Sun, X., Spalding, J., Kollef, M.H. Crit. Care (2009) [Pubmed]
  5. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Shorr, A.F., Williams, M.D. Thromb. Haemost. (2009) [Pubmed]
  6. Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. Shorr, A.F., Owens, R.C. Am. J. Health. Syst. Pharm (2009) [Pubmed]
  7. Quality pneumonia care: distinguishing community-acquired from health care-associated pneumonia. Shorr, A.F., Owens, R.C. Am. J. Health. Syst. Pharm (2009) [Pubmed]
  8. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Shorr, A.F., Zilberberg, M.D., Micek, S.T., Kollef, M.H. Arch. Intern. Med. (2008) [Pubmed]
  9. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). Shorr, A.F., Nelson, D.R., Wyncoll, D.L., Reinhart, K., Brunkhorst, F., Vail, G.M., Janes, J. Crit. Care (2008) [Pubmed]
  10. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Shorr, A.F., Micek, S.T., Kollef, M.H. Crit. Care Med. (2008) [Pubmed]
  11. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications. Shorr, A.F., Doyle, J., Stern, L., Dolgitser, M., Zilberberg, M.D. Curr. Med. Res. Opin (2008) [Pubmed]
  12. The pharmacoeconomics of deep vein thrombosis treatment. Shorr, A.F. Am. J. Med. (2007) [Pubmed]
  13. Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. Shorr, A.F., Jackson, W.L., Moores, L.K., Warkentin, T.E. J. Thromb. Thrombolysis (2007) [Pubmed]
  14. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis. Shorr, A.F., Jackson, W.L., Weiss, B.M., Moores, L.K. Blood Coagul. Fibrinolysis (2007) [Pubmed]
  15. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. Shorr, A.F., Sarnes, M.W., Peeples, P.J., Stanford, R.H., Happe, L.E., Farrelly, E. Am. J. Health. Syst. Pharm (2007) [Pubmed]
  16. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Shorr, A.F., Kwong, L.M., Sarnes, M., Happe, L., Farrelly, E., Mody-Patel, N. Thromb. Res. (2007) [Pubmed]
  17. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Shorr, A.F., Micek, S.T., Jackson, W.L., Kollef, M.H. Crit. Care Med. (2007) [Pubmed]
  18. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Shorr, A.F., Lazarus, D.R., Sherner, J.H., Jackson, W.L., Morrel, M., Fraser, V.J., Kollef, M.H. Crit. Care Med. (2007) [Pubmed]
  19. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Shorr, A.F., Wainright, J.L., Cors, C.S., Lettieri, C.J., Nathan, S.D. Eur. Respir. J. (2007) [Pubmed]
  20. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Shorr, A.F., Khashab, M.M., Xiang, J.X., Tennenberg, A.M., Kahn, J.B. Respir. Med (2006) [Pubmed]
  21. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Shorr, A.F., Bernard, G.R., Dhainaut, J.F., Russell, J.R., Macias, W.L., Nelson, D.R., Sundin, D.P. Crit. Care (2006) [Pubmed]
  22. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Shorr, A.F., Tabak, Y.P., Gupta, V., Johannes, R.S., Liu, L.Z., Kollef, M.H. Crit. Care (2006) [Pubmed]
  23. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Shorr, A.F., Bodi, M., Rodriguez, A., Sole-Violan, J., Garnacho-Montero, J., Rello, J. Chest (2006) [Pubmed]
  24. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Shorr, A.F., Susla, G.B., Kollef, M.H. Clin. Infect. Dis. (2005) [Pubmed]
  25. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Shorr, A.F., Zadeikis, N., Jackson, W.L., Ramage, A.S., Wu, S.C., Tennenberg, A.M., Kollef, M.H. Clin. Infect. Dis. (2005) [Pubmed]
  26. Preventing pneumonia: the role for pneumococcal and influenza vaccines. Shorr, A.F. Clin. Chest Med. (2005) [Pubmed]
  27. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Shorr, A.F., Helman, D.L., Davies, D.B., Nathan, S.D. Eur. Respir. J. (2005) [Pubmed]
  28. Transfusion practice and blood stream infections in critically ill patients. Shorr, A.F., Jackson, W.L., Kelly, K.M., Fu, M., Kollef, M.H. Chest (2005) [Pubmed]
  29. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Shorr, A.F., Chung, K., Jackson, W.L., Waterman, P.E., Kollef, M.H. Crit. Care Med. (2005) [Pubmed]
  30. Transfusion practice and nosocomial infection: assessing the evidence. Shorr, A.F., Jackson, W.L. Curr. Opin. Crit. Care (2005) [Pubmed]
  31. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Shorr, A.F., Zadeikis, N., Xiang, J.X., Tennenberg, A.M., Wes Ely, E. Clin. Ther (2005) [Pubmed]
  32. Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Shorr, A.F., Susla, G.M., O'Grady, N.P. Chest (2004) [Pubmed]
  33. Sarcoidosis, race, and short-term outcomes following lung transplantation. Shorr, A.F., Helman, D.L., Davies, D.B., Nathan, S.D. Chest (2004) [Pubmed]
  34. Depreotide scanning in sarcoidosis: a pilot study. Shorr, A.F., Helman, D.L., Lettieri, C.J., Montilla, J.L., Bridwell, R.S. Chest (2004) [Pubmed]
  35. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. Shorr, A.F., Scoville, S.L., Cersovsky, S.B., Shanks, G.D., Ockenhouse, C.F., Smoak, B.L., Carr, W.W., Petruccelli, B.P. JAMA (2004) [Pubmed]
  36. New choices for central venous catheters: potential financial implications. Shorr, A.F., Humphreys, C.W., Helman, D.L. Chest (2003) [Pubmed]
  37. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Shorr, A.F., Davies, D.B., Nathan, S.D. Chest (2003) [Pubmed]
  38. D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Shorr, A.F., Thomas, S.J., Alkins, S.A., Fitzpatrick, T.M., Ling, G.S. Chest (2002) [Pubmed]
  39. An update on cost-effectiveness analysis in critical care. Shorr, A.F. Curr. Opin. Crit. Care (2002) [Pubmed]
  40. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia : potential economic implications. Shorr, A.F., O'Malley, P.G. Chest (2001) [Pubmed]
  41. Endobronchial biopsy for sarcoidosis: a prospective study. Shorr, A.F., Torrington, K.G., Hnatiuk, O.W. Chest (2001) [Pubmed]
  42. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Shorr, A.F., Torrington, K.G., Hnatiuk, O.W. Chest (2001) [Pubmed]
  43. Circulating D dimer in patients with sarcoidosis. Shorr, A.F., Hnatiuk, O.W. Chest (2000) [Pubmed]
 
WikiGenes - Universities